SEC 13F Intelligence

Managers / Q1 2021 · view latest →

KNOTT DAVID M

CIK 0000808722

Reported Value
$234M
Q1 2021
Positions
166
Filings on Record
12
2019–present window
Filed
May 13, 2021
original filing

Summary

Knott David M reported $234M in U.S.-listed holdings across 166 positions for Q1 2021.

Its largest position, Calumet Specialty Products Partners, represents 7.3% of the portfolio.

Compared with Q4 2020, the fund opened 41 new positions and exited 22.

Portfolio Metrics

Turnover
+23.4%
vs prior filed quarter
Top-10 Concentration
+47.2%
share of reported value
Largest Position
+7.3%
Calumet Specialty Products Partners
New / Exited
41 / 22
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $213MQ4 ’18Q1 ’19: $251MQ2 ’19: $237MQ2 ’19Q3 ’19: $238MQ4 ’19: $247MQ4 ’19Q1 ’20: $158MQ2 ’20: $183MQ2 ’20Q3 ’20: $170MQ4 ’20: $221MQ4 ’20Q1 ’21: $234MQ2 ’21: $281MQ2 ’21Q3 ’21: $275Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 56.5%Other: 25.8%MLP: 8.3%Ltd Part: 6.0%Unit: 2.1%Other: 1.2%
  • Common Stock · 56.5% · $132M
  • Other · 25.8% · $60M
  • MLP · 8.3% · $19M
  • Ltd Part · 6.0% · $14M
  • Unit · 2.1% · $5M
  • Other · 1.2% · $3M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2020 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
African Gold Acquistion Corp.NEW+618.0K618.0K+$6M$6M
Twelve Seas Investment Company IINEW+515.0K515.0K+$5M$5M
Glass Houses Acquisition Corp.NEW+500.0K500.0K+$5M$5M
Live Oak Mobility Aquisition Corp.NEW+360.2K360.2K+$4M$4M
Kairos Acquisition Corp.NEW+261.4K261.4K+$3M$3M
Capitol Investment Corp. VNEW+250.0K250.0K+$3M$3M
UTHUnited Therapeutics CorporationNEW+14.5K14.5K+$2M$2M
Medicus Science Acquisition, Corp.NEW+200.0K200.0K+$2M$2M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2021

49 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1Calumet Specialty Products Partners, LPCommon7.31%$17M2.80M
2UPLDEURUpland Software, Inc.history →Common6.06%$14M300.0K
3APOEURApollo Global Management, Inc.history →Common6.03%$14M300.0K
4FTAIEURFortress Trans & Infrastructure Inv. LLChistory →Common6.03%$14M500.0K
5GOOGAlphabet Inc-Cl Chistory →Common4.96%$12M5.6K
6LGNDLigand Pharmaceuticals Incorporatedhistory →Common4.89%$11M75.0K
7Danimer Scientific, Inc.Common3.23%$8M200.0K
8MDWTUSDMidwest Holding Inc.history →Common3.21%$7M150.0K
9FSKFS KKR Capital Corp.history →Common2.97%$7M350.0K
10African Gold Acquistion Corp.Common2.54%$6M600.0K
11Glass Houses Acquisition Corp.Common2.15%$5M500.0K
12Twelve Seas Investment Company IICommon2.11%$5M500.0K
13KKRKKR & Co. Inc.history →Common2.09%$5M100.0K
14PFEPfizer Inc.history →Common1.86%$4M119.9K
15Kennedy-Wilson Holdings, Inc.Common1.82%$4M210.0K
16Horizon Therapeutics Public Ltd. CompanyCommon1.60%$4M40.6K
17EBCEastern Bankshares Inchistory →Common1.57%$4M190.0K
18Live Oak Mobility Aquisition Corp.Common1.54%$4M360.2K
19GILDGilead Sciences, Inc.history →Common1.41%$3M50.9K
20BMYBristol-Myers Squibb Companyhistory →Common1.39%$3M51.4K
21KDMNKadmon Holdings, Inc.history →Common1.27%$3M762.0K
22XENEXenon Pharmaceuticals Inc.history →Common1.10%$3M144.1K
23Kairos Acquisition Corp.Common1.09%$3M261.4K
24Capitol Investment Corp. VCommon1.08%$3M250.0K
25TGTXTG Therapeutics, Inc.history →Common1.07%$3M52.0K
26Avadel Pharmaceuticals plcCommon1.06%$2M272.8K
27CLDNEUREiger BioPharmaceuticals, Inc.history →Common1.05%$2M276.5K
28UTHUnited Therapeutics Corporationhistory →Common1.04%$2M14.5K
29ZGNXEURZogenix, Inc.Common0.98%$2M117.7K
30ABBVAbbVie Inc.Common0.92%$2M19.8K
31TREURTrillium Therapeutics Inc.Common0.91%$2M198.7K
32Horizon Aquistion CorporationCommon0.89%$2M210.1K
33AUPHAurinia Pharmaceuticals Inc.Common0.86%$2M154.8K
34CNSTConstellation Pharmaceuticals, Inc.Common0.86%$2M85.9K
35Medicus Science Acquisition, Corp.Common0.84%$2M200.0K
36ABAllianceBernstein Holdings PL Unit LtdCommon0.84%$2M49.0K
37Tastemaker Acquisition Corp.Common0.83%$2M200.0K
38B. Riley Principal 150 Merger Corp.Common0.74%$2M173.0K
39International Gaming TechnologiesCommon0.69%$2M100.0K
40Kairos Acquisition Corp. WarrantsCommon0.64%$2M130.7K
41JPMJP Morgan ChaseCommon0.63%$1M9.8K
42ASLAN Pharmaceuticals LimitedCommon0.63%$1M437.4K
43CHRSCoherus Biosciences, Inc.Common0.62%$1M99.7K
44uniQure N.V.Common0.60%$1M41.8K
45VKTXViking Therapeutics, Inc.Common0.56%$1M208.1K
46Verrica Pharmaceuticals, Inc.Common0.51%$1M78.4K
47Tastemaker Acquisition Corp. WarrantsCommon0.49%$1M100.0K
48Cidara Therapeutics, Inc.Common0.47%$1M415.3K
49Roth CH Acquisition III Co.Common0.43%$1M100.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2021$275M197Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$281M195Aug 13, 202113F-HRchanges · EDGAR ↗
Q1 2021$234M166May 13, 202113F-HRchanges · EDGAR ↗
Q4 2020$221M145Feb 12, 202113F-HRchanges · EDGAR ↗
Q3 2020$170M135Nov 13, 202013F-HRchanges · EDGAR ↗
Q2 2020$183M127Aug 12, 202013F-HRchanges · EDGAR ↗
Q1 2020$158M156May 13, 202013F-HRchanges · EDGAR ↗
Q4 2019$247M152Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$238M157Nov 12, 201913F-HRchanges · EDGAR ↗
Q2 2019$237M148Aug 12, 201913F-HRchanges · EDGAR ↗
Q1 2019$251M143May 13, 201913F-HRchanges · EDGAR ↗
Q4 2018$213M133Feb 12, 201913F-HRchanges · EDGAR ↗

Other Included Managers

This filing reports holdings on behalf of 1 additional manager.

  • DORSET MANAGEMENT CORP028-10281

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.